SCHEMBL7743687

SCHEMBL7743687

COc1ccc2c(c1)CCN(CCc1ccccc1)C2

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.62
SIGMAR1 Q99720 3/20 0.60
DRD4 P21917 2/20 0.60
DRD3 P35462 2/20 0.60
CHRM2 P08172 1/20 0.60
HTR1A P08908 1/20 0.60
CHRM3 P20309 1/20 0.60
ADRA1D P25100 1/20 0.60
HTR2C P28335 1/20 0.60
ADRA1A P35348 1/20 0.60
ADRA1B P35368 1/20 0.60
HTR2B P41595 1/20 0.60
SLC6A3 Q01959 1/20 0.60
TMEM97 Q5BJF2 1/20 0.60
DHCR7 Q9UBM7 1/20 0.60
DRD1 P21728 1/20 0.59
DRD5 P21918 1/20 0.59
KCNH2 Q12809 1/20 0.59
OPRM1 P35372 1/20 0.56
OPRD1 P41143 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11466104 0.92 KCNH2 (0.68) SIGMAR1DRD4DRD3HTR1AHTR2C
Hydrochloric Acid SCHEMBL9852467 0.91 GRIN1 (0.60) SIGMAR1DRD4DRD3CHRM2HTR1A
SCHEMBL8789784 0.87 ABCB1 (0.63) ABCB1SIGMAR1SLC6A3DHCR7DRD1
SCHEMBL31174290 0.87 DHCR7 (0.60) ABCB1SIGMAR1DRD4DRD3CHRM2
SCHEMBL9852537 0.85 GRIN1 (0.62) SIGMAR1DRD4DRD3CHRM2HTR1A
SCHEMBL8506973 0.84 ABCB1 (0.71) ABCB1SIGMAR1DRD4DRD3CHRM2
SCHEMBL13896162 0.84 ABCB1 (0.73) ABCB1DHCR7
Hydrochloric Acid SCHEMBL9852474 0.83 ABCB1 (0.61) ABCB1SIGMAR1DRD4DRD3CHRM2
SCHEMBL28992946 0.83 ABCB1 (0.55) ABCB1DRD3SLC6A3DHCR7DRD1
SCHEMBL8790326 0.82 KCNJ1 (0.67) ABCB1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11505529-B2 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome NATIONAL TAIWAN UNIVERSITY (TW) 2022-11-22 US disclosed
EP-1045843-A4 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 2001-10-24 EP disclosed
EP-1045843-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2000-10-25 EP disclosed
US-5977134-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1999-11-02 US disclosed
WO-1999028313-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1999-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11505529-B2 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome HTR7, GPR27, HTR5A ABCB1 328/4885SIGMAR1 252/4885DRD4 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.